AU2016363718B2 - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer Download PDF

Info

Publication number
AU2016363718B2
AU2016363718B2 AU2016363718A AU2016363718A AU2016363718B2 AU 2016363718 B2 AU2016363718 B2 AU 2016363718B2 AU 2016363718 A AU2016363718 A AU 2016363718A AU 2016363718 A AU2016363718 A AU 2016363718A AU 2016363718 B2 AU2016363718 B2 AU 2016363718B2
Authority
AU
Australia
Prior art keywords
methoxy
phenyl
thiadiazol
amino
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016363718A
Other languages
English (en)
Other versions
AU2016363718A1 (en
Inventor
Mark David Charles
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
AstraZeneca AB
Original Assignee
Cancer Research Technology Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, AstraZeneca AB filed Critical Cancer Research Technology Ltd
Publication of AU2016363718A1 publication Critical patent/AU2016363718A1/en
Application granted granted Critical
Publication of AU2016363718B2 publication Critical patent/AU2016363718B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016363718A 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer Active AU2016363718B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30
US62/260,789 2015-11-30
PCT/EP2016/079250 WO2017093299A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
AU2016363718A1 AU2016363718A1 (en) 2018-07-12
AU2016363718B2 true AU2016363718B2 (en) 2019-11-14

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016363718A Active AU2016363718B2 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (23)

Country Link
US (3) US10323028B2 (enExample)
EP (1) EP3383873B1 (enExample)
JP (1) JP6999550B2 (enExample)
KR (1) KR20180083942A (enExample)
CN (1) CN108349966B (enExample)
AR (1) AR106874A1 (enExample)
AU (1) AU2016363718B2 (enExample)
BR (1) BR112018010806A2 (enExample)
CA (1) CA3005495C (enExample)
CL (1) CL2018001407A1 (enExample)
CO (1) CO2018006928A2 (enExample)
EA (1) EA201891241A1 (enExample)
ES (1) ES2914333T3 (enExample)
IL (1) IL259510A (enExample)
MX (1) MX2018006532A (enExample)
NI (1) NI201800064A (enExample)
PH (1) PH12018501131A1 (enExample)
RU (1) RU2018123714A (enExample)
SG (1) SG11201803810XA (enExample)
SV (1) SV2018005702A (enExample)
TN (1) TN2018000127A1 (enExample)
TW (1) TW201733587A (enExample)
WO (1) WO2017093299A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US11254666B2 (en) 2017-06-13 2022-02-22 Medshine Discovery Inc. Compound as GLS1 inhibitor
EP3868758B1 (en) 2018-10-16 2023-01-04 Medshine Discovery Inc. Thiadiazole derivatives and use thereof as a gls1 inhibitors for the treatment of cancer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2015101957A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel glutaminase inhibitors
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2013344560B2 (en) * 2012-11-16 2017-09-14 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2015101957A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel glutaminase inhibitors
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
SV2018005702A (es) 2018-11-27
ES2914333T3 (es) 2022-06-09
SG11201803810XA (en) 2018-06-28
NI201800064A (es) 2018-10-18
EP3383873B1 (en) 2022-03-09
CA3005495C (en) 2023-12-12
CN108349966B (zh) 2022-02-15
JP6999550B2 (ja) 2022-02-10
CO2018006928A2 (es) 2018-10-10
AR106874A1 (es) 2018-02-28
US20210246131A1 (en) 2021-08-12
BR112018010806A2 (pt) 2018-11-27
US11753405B2 (en) 2023-09-12
CL2018001407A1 (es) 2018-10-12
JP2018535986A (ja) 2018-12-06
KR20180083942A (ko) 2018-07-23
IL259510A (en) 2018-07-31
WO2017093299A1 (en) 2017-06-08
CA3005495A1 (en) 2017-06-08
EP3383873A1 (en) 2018-10-10
CN108349966A (zh) 2018-07-31
RU2018123714A (ru) 2020-01-09
AU2016363718A1 (en) 2018-07-12
MX2018006532A (es) 2019-05-15
US20170152255A1 (en) 2017-06-01
US10323028B2 (en) 2019-06-18
EA201891241A1 (ru) 2019-01-31
PH12018501131A1 (en) 2019-01-21
US10981904B2 (en) 2021-04-20
TW201733587A (zh) 2017-10-01
US20190389853A1 (en) 2019-12-26
TN2018000127A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
AU2016363718B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
US10294221B2 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
AU2016361834B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
AU2016363719B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
US10577354B2 (en) Bis-pyridazine compounds and their use in treating cancer
HK1260708B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260708A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1232529B (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
HK1232529A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)